世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界および日本の子宮疾患治療薬の市場規模、現状、予測2021-2027年


Global and Japan Uterine Diseases Therapeutics Market Size, Status and Forecast 2021-2027

子宮は女性の生殖系にある筋肉の器官で、女性の生殖や胎児の発育に大きな役割を果たしています。子宮疾患の発生率も非常に高いため、子宮疾患の治療は特に重要です。 市場分析とインサイト子宮疾患治療薬の世... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2021年11月19日 US$3,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

子宮は女性の生殖系にある筋肉の器官で、女性の生殖や胎児の発育に大きな役割を果たしています。子宮疾患の発生率も非常に高いため、子宮疾患の治療は特に重要です。

市場分析とインサイト子宮疾患治療薬の世界市場
子宮疾患治療薬の世界市場規模は、2020年のXX百万米ドルから、2021-2027年の間にXX%のCAGRで、2027年にXX百万米ドルに達すると予測されます。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界の子宮疾患治療薬市場で得られる主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つよう、見事な試みを行っています。本レポートの購入者は、収益面での世界の子宮疾患治療薬市場全体の規模など、検証済みの信頼できる市場予測にアクセスすることができます。
全体として、本レポートは、プレイヤーが競合他社に対して優位に立ち、世界の子宮疾患治療薬市場で永続的な成功を収めるために利用できる効果的なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、世界のUterine Diseases Therapeutics市場を詳細に調査するために、ユニークで業界最高の調査・分析アプローチを採用しました。

世界の子宮疾患治療薬の範囲と市場規模
子宮疾患治療薬市場は、企業別、地域(国)別、タイプ別、用途別に分類されています。世界のUterine Diseases Therapeutics(子宮疾患治療薬)市場のプレーヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間で、タイプ別とアプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
薬剤による治療法
外科的治療薬

アプリケーション別セグメント
病院
クリニック
その他

地域別
北アメリカ
U.S.
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
アボット
メルク
GlaxoSmithKline(グラクソ・スミスクライン
ファイザー
アストラゼネカ
ロシュ
ノバルティス
アッヴィ
ニューロクライムバイオサイエンス
ブリストル・マイヤーズ スクイブ(Bristol-Myers Squibb
マイオバント・サイエンス
イーライリリー


ページTOPに戻る


目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Diseases Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medicinal Treatments
1.2.3 Surgical Treatments
1.3 Market by Application
1.3.1 Global Uterine Diseases Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Uterine Diseases Therapeutics Market Perspective (2016-2027)
2.2 Uterine Diseases Therapeutics Growth Trends by Regions
2.2.1 Uterine Diseases Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Uterine Diseases Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Uterine Diseases Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Uterine Diseases Therapeutics Industry Dynamic
2.3.1 Uterine Diseases Therapeutics Market Trends
2.3.2 Uterine Diseases Therapeutics Market Drivers
2.3.3 Uterine Diseases Therapeutics Market Challenges
2.3.4 Uterine Diseases Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Uterine Diseases Therapeutics Players by Revenue
3.1.1 Global Top Uterine Diseases Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Uterine Diseases Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Uterine Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Diseases Therapeutics Revenue
3.4 Global Uterine Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Uterine Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Diseases Therapeutics Revenue in 2020
3.5 Uterine Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Uterine Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Uterine Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Uterine Diseases Therapeutics Breakdown Data by Type
4.1 Global Uterine Diseases Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Type (2022-2027)

5 Uterine Diseases Therapeutics Breakdown Data by Application
5.1 Global Uterine Diseases Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Uterine Diseases Therapeutics Market Size (2016-2027)
6.2 North America Uterine Diseases Therapeutics Market Size by Type
6.2.1 North America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
6.3 North America Uterine Diseases Therapeutics Market Size by Application
6.3.1 North America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
6.4 North America Uterine Diseases Therapeutics Market Size by Country
6.4.1 North America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Uterine Diseases Therapeutics Market Size (2016-2027)
7.2 Europe Uterine Diseases Therapeutics Market Size by Type
7.2.1 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Uterine Diseases Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2027)
7.3 Europe Uterine Diseases Therapeutics Market Size by Application
7.3.1 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Uterine Diseases Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2027)
7.4 Europe Uterine Diseases Therapeutics Market Size by Country
7.4.1 Europe Uterine Diseases Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Uterine Diseases Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Uterine Diseases Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Uterine Diseases Therapeutics Market Size (2016-2027)
9.2 Latin America Uterine Diseases Therapeutics Market Size by Type
9.2.1 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Uterine Diseases Therapeutics Market Size by Application
9.3.1 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Uterine Diseases Therapeutics Market Size by Country
9.4.1 Latin America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Uterine Diseases Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbot
11.1.1 Abbot Company Details
11.1.2 Abbot Business Overview
11.1.3 Abbot Uterine Diseases Therapeutics Introduction
11.1.4 Abbot Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.1.5 Abbot Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Uterine Diseases Therapeutics Introduction
11.2.4 Merck Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.2.5 Merck Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Uterine Diseases Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Uterine Diseases Therapeutics Introduction
11.4.4 Pfizer Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Uterine Diseases Therapeutics Introduction
11.5.4 AstraZeneca Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Uterine Diseases Therapeutics Introduction
11.6.4 Roche Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Uterine Diseases Therapeutics Introduction
11.7.4 Novartis Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Uterine Diseases Therapeutics Introduction
11.8.4 AbbVie Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Neurocrime Biosciences
11.9.1 Neurocrime Biosciences Company Details
11.9.2 Neurocrime Biosciences Business Overview
11.9.3 Neurocrime Biosciences Uterine Diseases Therapeutics Introduction
11.9.4 Neurocrime Biosciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.9.5 Neurocrime Biosciences Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Uterine Diseases Therapeutics Introduction
11.10.4 Bristol-Myers Squibb Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 Myovant Sciences
11.11.1 Myovant Sciences Company Details
11.11.2 Myovant Sciences Business Overview
11.11.3 Myovant Sciences Uterine Diseases Therapeutics Introduction
11.11.4 Myovant Sciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.11.5 Myovant Sciences Recent Development
11.12 Eli Lily
11.12.1 Eli Lily Company Details
11.12.2 Eli Lily Business Overview
11.12.3 Eli Lily Uterine Diseases Therapeutics Introduction
11.12.4 Eli Lily Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.12.5 Eli Lily Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る


 

Summary

Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important.

Market Analysis and Insights: Global Uterine Diseases Therapeutics Market
The global Uterine Diseases Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Uterine Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Uterine Diseases Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Uterine Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Uterine Diseases Therapeutics market.

Global Uterine Diseases Therapeutics Scope and Market Size
Uterine Diseases Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medicinal Treatments
Surgical Treatments

Segment by Application
Hospital
Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbot
Merck
GlaxoSmithKline
Pfizer
AstraZeneca
Roche
Novartis
AbbVie
Neurocrime Biosciences
Bristol-Myers Squibb
Myovant Sciences
Eli Lily



ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Diseases Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medicinal Treatments
1.2.3 Surgical Treatments
1.3 Market by Application
1.3.1 Global Uterine Diseases Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Uterine Diseases Therapeutics Market Perspective (2016-2027)
2.2 Uterine Diseases Therapeutics Growth Trends by Regions
2.2.1 Uterine Diseases Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Uterine Diseases Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Uterine Diseases Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Uterine Diseases Therapeutics Industry Dynamic
2.3.1 Uterine Diseases Therapeutics Market Trends
2.3.2 Uterine Diseases Therapeutics Market Drivers
2.3.3 Uterine Diseases Therapeutics Market Challenges
2.3.4 Uterine Diseases Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Uterine Diseases Therapeutics Players by Revenue
3.1.1 Global Top Uterine Diseases Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Uterine Diseases Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Uterine Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Diseases Therapeutics Revenue
3.4 Global Uterine Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Uterine Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Diseases Therapeutics Revenue in 2020
3.5 Uterine Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Uterine Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Uterine Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Uterine Diseases Therapeutics Breakdown Data by Type
4.1 Global Uterine Diseases Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Type (2022-2027)

5 Uterine Diseases Therapeutics Breakdown Data by Application
5.1 Global Uterine Diseases Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Uterine Diseases Therapeutics Market Size (2016-2027)
6.2 North America Uterine Diseases Therapeutics Market Size by Type
6.2.1 North America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
6.3 North America Uterine Diseases Therapeutics Market Size by Application
6.3.1 North America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
6.4 North America Uterine Diseases Therapeutics Market Size by Country
6.4.1 North America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Uterine Diseases Therapeutics Market Size (2016-2027)
7.2 Europe Uterine Diseases Therapeutics Market Size by Type
7.2.1 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Uterine Diseases Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2027)
7.3 Europe Uterine Diseases Therapeutics Market Size by Application
7.3.1 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Uterine Diseases Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2027)
7.4 Europe Uterine Diseases Therapeutics Market Size by Country
7.4.1 Europe Uterine Diseases Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Uterine Diseases Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Uterine Diseases Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Uterine Diseases Therapeutics Market Size (2016-2027)
9.2 Latin America Uterine Diseases Therapeutics Market Size by Type
9.2.1 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Uterine Diseases Therapeutics Market Size by Application
9.3.1 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Uterine Diseases Therapeutics Market Size by Country
9.4.1 Latin America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Uterine Diseases Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbot
11.1.1 Abbot Company Details
11.1.2 Abbot Business Overview
11.1.3 Abbot Uterine Diseases Therapeutics Introduction
11.1.4 Abbot Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.1.5 Abbot Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Uterine Diseases Therapeutics Introduction
11.2.4 Merck Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.2.5 Merck Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Uterine Diseases Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Uterine Diseases Therapeutics Introduction
11.4.4 Pfizer Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Uterine Diseases Therapeutics Introduction
11.5.4 AstraZeneca Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Uterine Diseases Therapeutics Introduction
11.6.4 Roche Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Uterine Diseases Therapeutics Introduction
11.7.4 Novartis Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Uterine Diseases Therapeutics Introduction
11.8.4 AbbVie Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Neurocrime Biosciences
11.9.1 Neurocrime Biosciences Company Details
11.9.2 Neurocrime Biosciences Business Overview
11.9.3 Neurocrime Biosciences Uterine Diseases Therapeutics Introduction
11.9.4 Neurocrime Biosciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.9.5 Neurocrime Biosciences Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Uterine Diseases Therapeutics Introduction
11.10.4 Bristol-Myers Squibb Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 Myovant Sciences
11.11.1 Myovant Sciences Company Details
11.11.2 Myovant Sciences Business Overview
11.11.3 Myovant Sciences Uterine Diseases Therapeutics Introduction
11.11.4 Myovant Sciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.11.5 Myovant Sciences Recent Development
11.12 Eli Lily
11.12.1 Eli Lily Company Details
11.12.2 Eli Lily Business Overview
11.12.3 Eli Lily Uterine Diseases Therapeutics Introduction
11.12.4 Eli Lily Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.12.5 Eli Lily Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る